Antibodies directed against lymphocyte activation gene 3 (LAG-3)
US10836824B2 · kind B2 · utility
0Cited by
11References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2016 |
| Grant date | Nov 17, 2020 |
| Priority date | — |
| Expiry date | Jan 3, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the Lymphocyte Activation Gene-3 (LAG-3). The invention provides a LAG-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the LAG-3-binding agent to treat a disorder or disease that is responsive to LAG-3 inhibition, such as cancer or an infectious disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.